AR070539A1 - Inhibidores de la actividad de proteina tirosina quinasa - Google Patents
Inhibidores de la actividad de proteina tirosina quinasaInfo
- Publication number
- AR070539A1 AR070539A1 ARP090100693A ARP090100693A AR070539A1 AR 070539 A1 AR070539 A1 AR 070539A1 AR P090100693 A ARP090100693 A AR P090100693A AR P090100693 A ARP090100693 A AR P090100693A AR 070539 A1 AR070539 A1 AR 070539A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- group
- independently selected
- integer
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 18
- 125000000217 alkyl group Chemical group 0.000 abstract 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 8
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 230000001575 pathological effect Effects 0.000 abstract 2
- 230000011664 signaling Effects 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 102000009465 Growth Factor Receptors Human genes 0.000 abstract 1
- 108010009202 Growth Factor Receptors Proteins 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 108091008605 VEGF receptors Proteins 0.000 abstract 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 125000006239 protecting group Chemical group 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000004953 trihalomethyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La presente se refiere a compuestos que inhiben la actividad de la proteína tirosina quinasa. En particular se refiere a compuestos que inhiben la actividad de la proteína tirosina quinasa de receptores del factor de crecimiento, dando por resultado la inhibicion de la senalizacion de receptores, por ejemplo, la inhibicion de la senalizacion del receptor VEGF. También proporciona compuestos, composiciones y métodos para tratar enfermedades y condiciones patologicas proliferativas celulares y enfermedades, trastornos y condiciones patologicas oftalmologicas. Reivindicacion 1: Un compuesto de la formula (1) y N-oxidos, hidratos, solvatos, sales farmacéuticamente aceptables, profármacos y complejos de ellos, y mezclas racémicas y escalémicas, sus diastereomeros y enantiomeros, en donde D está seleccionado del grupo que consiste en un sistema de anillos aromáticos, heteroaromáticos, cicloalquilos o heterocíclicos, cada uno de los cuales está opcionalmente sustituido con 1 a 5 seleccionados de modo independiente R38; M es un resto heterocíclico fusionado opcionalmente sustituido; Z es -O-; Ar es un sistema de anillos aromáticos de 5 a 7 miembros, que está opcionalmente sustituido con 0 a 4 grupos R2: y G es un grupo B-L-T, en donde B es -N(R13)- o -C(=S)-; L está seleccionado del grupo que consiste en -C(=O)N(R13)-, -C(=O)alquil C0-1-C(=O)N(R13)-, y -C(=O)-, en donde un grupo alquilo del grupo L antes mencionado está opcionalmente sustituido; y T está seleccionado del grupo que consiste en -alquilo C0-5, -alquil C0-5-Q, -O-alquil C0-5-Q, -O-alquilo C0-5, -C(=S)-N(R13)-alquil C0-5-Q, -alquil C0-5-S(O)2-Q y -C(=S)-N(R13)-alquilo C0-5, en donde cada alquilo C0-5 está opcionalmente sustituido; en donde cada R38 está seleccionado, de modo independiente, del grupo que consiste en halo, alquilo C1-C6 opcionalmente sustituido, -alquil C0-6-(heterociclo opcionalmente sustituido), -alquenil C2-6=N-heterociclo-alquilo C1-6 opcionalmente sustituido, -CH=N-heterociclo opcionalmente sustituido, -(CH2)jNR39(CH2)nR36, -C(O)(CH2)jNR39(CH2)nR36, -(CH2)jNR39(CH2)i[O(CH2)i]x(CH2)jR99, -(CH2)jNR39C(O)(CH2)jO(CH2)jOR3, -(CH2)jNR39(CH)(CH3)(CH2)jR99 y -(CH2)jNR39(CH2)jCOOH; en donde cada j es un numero entero que va, de modo independiente, de 0 a 4, n es un numero entero que va de 0 a 6, x es un numero entero que va de 0-6, cada i es, de modo independiente, 2 o 3, y los restos -(CH2)n- de los grupos anteriores R38 están opcionalmente sustituidos con alquilo C1-6; R36 es H o -(CH2)n3OR37; en donde n3 es un numero entero que va de 0 a 6; con la condicion de que, cuando R36 y R39 están unidos ambos al mismo nitrogeno, entonces R36 y R39 no estén ambos unidos al nitrogeno directamente a través de un oxígeno; cada R37 está seleccionado, de modo independiente, de H, alquilo C1-6, -(CH2)nO(CH2)aO-alquilo C1-6, -(CH2)nCH(NH)(CH2)nO-alquilo C1-6, -(CH2)nCH(NH)(CH2)nalquilo C1-6, -(CH2)nO(CH2)aO-cicloalquiIo C3-10, -(CH2)nCH(NH)(CH2)nO-cicloalquilo C3-10 y -(CH2)nCH(NH)(CH2)ncicloalquilo C3-10, en donde cada n es un numero entero que va, de modo independiente, de 0 a 6 y a es un numero entero que va de 2 a 6, en donde los restos de alquilo y cicloalquilo de los grupos anteriores R37 están opcionalmente sustituidos con uno o varios sustituyentes seleccionados de modo independiente; R39 está seleccionado del grupo que consiste en H, alquilo C1-6, -SO2-alquilo C1-6, -C(O)-alquilo C1-6, -C(O)O-alquilo C1-6, -C(O)-alquil C1-6-NR3R3, -alquil C1-C6-O-alquilo C1-6, -C(O)(CH2)0-4O(CH2)1-4Oalquilo C1-6, -C(O)-alquil C1-6-OH, -C(O)-CF3 y -C(O)CH[CH(alquil C1-6)2]NR3R3 y un grupo protector usado para proteger grupos amino secundarios, con la condicion de que, cuando R36 y R39 están unidos ambos al mismo nitrogeno, entonces R36 y R39 no estén ambos unidos al nitrogeno directamente a través de un oxígeno; R99 en cada aparicion es, de modo independiente, -H, -NH2 u -OR3; R2 en cada aparicion está seleccionado, de modo independiente, de -H y halogeno; cada R3 está seleccionado, de modo independiente, del grupo que consiste en -H y R4; R4 es alquilo C1-6; cada R13 está seleccionado, de modo independiente, del grupo que consiste en -H, -C(O)NR3R3 y alquilo C1-6; Q es un sistema de anillos de tres a diez miembros, opcionalmente sustituido con cero a cuatro de R20; cada R20 está seleccionado, de modo independiente, del grupo que consiste en -H, halogeno, trihalometilo, -OR3, -S(O)0-2R3, -S(O)2NR3R3, -C(O)OR3, -C(O)NR3R3, -(CH2)0-5(heteroarilo), alquilo C1-6, -(CH2)nP(=O)(alquilo C1-6)2, en donde n es un numero entero que va de 0 a 6, y el heteroarilo y el alquilo C1-6 están opcionalmente sustituidos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3400508P | 2008-03-05 | 2008-03-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070539A1 true AR070539A1 (es) | 2010-04-14 |
Family
ID=41055503
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100693A AR070539A1 (es) | 2008-03-05 | 2009-02-27 | Inhibidores de la actividad de proteina tirosina quinasa |
| ARP100104383A AR079208A2 (es) | 2008-03-05 | 2010-11-26 | Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100104383A AR079208A2 (es) | 2008-03-05 | 2010-11-26 | Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US8729268B2 (es) |
| EP (2) | EP2262815A4 (es) |
| JP (2) | JP2011513339A (es) |
| KR (2) | KR20100132068A (es) |
| CN (2) | CN102015723B (es) |
| AR (2) | AR070539A1 (es) |
| AU (2) | AU2009221583B2 (es) |
| BR (2) | BRPI0908573A2 (es) |
| CA (2) | CA2717816A1 (es) |
| CO (1) | CO6290684A2 (es) |
| IL (2) | IL207946A0 (es) |
| MX (1) | MX2010009729A (es) |
| NZ (2) | NZ588355A (es) |
| RU (2) | RU2533827C2 (es) |
| SG (1) | SG182146A1 (es) |
| TW (2) | TW200940549A (es) |
| UA (2) | UA101362C2 (es) |
| WO (1) | WO2009109035A1 (es) |
| ZA (2) | ZA201005868B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2262815A4 (en) * | 2008-03-05 | 2012-04-11 | Methylgene Inc | Inhibitors of protein intolerance activity |
| CA2772625A1 (en) * | 2009-09-03 | 2011-03-10 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| US9340555B2 (en) | 2009-09-03 | 2016-05-17 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| JP2013525286A (ja) * | 2010-04-16 | 2013-06-20 | メチルジーン・インコーポレイテッド | タンパク質チロシンキナーゼ活性の阻害剤 |
| CA2802042A1 (en) * | 2010-06-09 | 2011-12-15 | Abbott Laboratories | Crystalline forms of kinase inhibitors |
| TWI492949B (zh) * | 2010-06-09 | 2015-07-21 | Abbvie Bahamas Ltd | 結晶型激酶抑制劑 |
| TWI482770B (zh) * | 2010-06-09 | 2015-05-01 | Abbvie Bahamas Ltd | 結晶型激酶抑制劑 |
| JP5789300B2 (ja) * | 2010-08-27 | 2015-10-07 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | フロピリジン誘導体 |
| US9056832B2 (en) * | 2010-09-17 | 2015-06-16 | Purdue Pharma L.P. | Pyridine compounds and the users thereof |
| BRPI1004176A2 (pt) * | 2010-10-25 | 2015-08-11 | Univ Rio De Janeiro | Compostos aril e/ou hetero aril uréias funcionalizados; processo de síntese desses composto; composição farmacêutica contendo tais compostos e usos |
| US20130096088A1 (en) * | 2011-09-30 | 2013-04-18 | Methylgene Inc. | Inhibitors of Protein Tyrosine Kinase Activity |
| US20130096135A1 (en) * | 2011-09-30 | 2013-04-18 | Methylgene Inc. | Selected Inhibitors of Protein Tyrosine Kinase Activity |
| US20130090327A1 (en) * | 2011-09-30 | 2013-04-11 | Methylgene Inc. | Inhibitors of Protein Tyrosine Kinase Activity |
| CN111620861A (zh) * | 2014-12-09 | 2020-09-04 | 艾伯维公司 | 具有低细胞渗透性的bcl-xl抑制性化合物以及包括它的抗体药物缀合物 |
| FR3037957B1 (fr) * | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CA3089630A1 (en) | 2018-01-31 | 2019-08-08 | Deciphera Pharmaceuticals, Llc | Combination therapy for the treatment of mastocytosis |
| SG11202007198WA (en) | 2018-01-31 | 2020-08-28 | Deciphera Pharmaceuticals Llc | Combination therapy for the treatment of gastrointestinal stromal tumors |
| TW202122082A (zh) | 2019-08-12 | 2021-06-16 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
| MX2022001863A (es) | 2019-08-12 | 2022-05-30 | Deciphera Pharmaceuticals Llc | Metodos para tratar los tumores del estroma gastrointestinal. |
| KR20220123058A (ko) | 2019-12-30 | 2022-09-05 | 데시페라 파마슈티칼스, 엘엘씨. | 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의 조성물 |
| DK4084778T3 (da) | 2019-12-30 | 2023-12-11 | Deciphera Pharmaceuticals Llc | Amorfe kinaseinhibitorformuleringer og fremgangsmåder til anvendelse deraf |
| WO2023155777A1 (en) * | 2022-02-15 | 2023-08-24 | Beigene (Suzhou) Co., Ltd. | N- [ (6-bromopyridin-3-yl) methyl] -2-methoxyethan-1-amine salts and preparation thereof |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7019A (en) * | 1850-01-15 | Improvement in obstetrical supporters | ||
| US7000A (en) * | 1850-01-08 | Smut-machine | ||
| US6107300A (en) | 1996-03-27 | 2000-08-22 | Dupont Pharmaceuticals | Arylamino fused pyrimidines |
| EP1028964A1 (en) | 1997-11-11 | 2000-08-23 | Pfizer Products Inc. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
| BR9910864A (pt) | 1998-06-04 | 2002-02-05 | Abbott Lab | Compostos anti-inflamatórios para inibição de aderência celular |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| EP1181296A1 (en) | 1999-06-03 | 2002-02-27 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| WO2001094353A1 (en) | 2000-06-06 | 2001-12-13 | Pfizer Products Inc. | Thiophene derivatives useful as anticancer agents |
| US20020004511A1 (en) | 2000-06-28 | 2002-01-10 | Luzzio Michael Joseph | Thiophene derivatives useful as anticancer agents |
| KR100600550B1 (ko) * | 2000-10-20 | 2006-07-13 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
| GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| US6995171B2 (en) | 2001-06-21 | 2006-02-07 | Agouron Pharmaceuticals, Inc. | Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents |
| JP2005527511A (ja) | 2002-03-01 | 2005-09-15 | ファイザー インコーポレイテッド | 抗血管形成剤として有用なチエノピリジンのインドリル−尿素誘導体およびその使用法 |
| US20030199525A1 (en) | 2002-03-21 | 2003-10-23 | Hirst Gavin C. | Kinase inhibitors |
| CL2003002287A1 (es) | 2002-11-25 | 2005-01-14 | Wyeth Corp | COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS |
| US20050065171A1 (en) | 2003-06-25 | 2005-03-24 | Shakespeare William C. | Substituted purine derivatives |
| MXPA06002296A (es) | 2003-08-29 | 2006-05-22 | Pfizer | Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos. |
| US7581674B2 (en) | 2003-11-21 | 2009-09-01 | Charles Cohen | Financial transaction system and method |
| JP2007518823A (ja) | 2004-01-23 | 2007-07-12 | アムゲン インコーポレイテッド | キノリン、キナゾリン、ピリジン、及びピリミジン化合物と炎症、血管新生、及び癌に対する治療におけるそれら化合物の用途 |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
| WO2005121125A1 (en) * | 2004-06-09 | 2005-12-22 | Pfizer Inc. | Ether-linked heteroaryl compounds |
| US20050288290A1 (en) | 2004-06-28 | 2005-12-29 | Borzilleri Robert M | Fused heterocyclic kinase inhibitors |
| US7439246B2 (en) | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| WO2006014325A2 (en) | 2004-07-02 | 2006-02-09 | Exelixis, Inc. | C-met modulators and method of use |
| ATE485300T1 (de) | 2004-07-16 | 2010-11-15 | Sunesis Pharmaceuticals Inc | Als aurora-kinase-inhibitoren nutzbare thienopyrimidine |
| ES2438017T3 (es) * | 2004-07-30 | 2014-01-15 | Methylgene Inc. | Inhibidores de la señalización del receptor del VEGF y del receptor del HGF |
| MX2007006230A (es) | 2004-11-30 | 2007-07-25 | Amgen Inc | Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer. |
| AU2006229343A1 (en) * | 2005-03-28 | 2006-10-05 | Kirin Pharma Kabushiki Kaisha | Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency |
| AU2006231646A1 (en) | 2005-04-06 | 2006-10-12 | Exelixis, Inc. | C-Met modulators and methods of use |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| BRPI0610322B8 (pt) * | 2005-05-20 | 2021-05-25 | Methylgene Inc | inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica |
| CA2608726C (en) | 2005-05-20 | 2013-07-09 | Methylgene Inc. | Inhibitors of vegf receptor and hgf receptor signaling |
| TW200740820A (en) * | 2005-07-05 | 2007-11-01 | Takeda Pharmaceuticals Co | Fused heterocyclic derivatives and use thereof |
| JP2009526761A (ja) * | 2006-01-30 | 2009-07-23 | アレイ バイオファーマ、インコーポレイテッド | ヘテロ二環式チオフェン化合物および使用の方法 |
| WO2007107005A1 (en) | 2006-03-22 | 2007-09-27 | Methylgene, Inc. | Inhibitors of protein tyrosine kinase activity |
| US7298968B1 (en) * | 2007-01-05 | 2007-11-20 | Rheem Manufacturing Company | Pumpless combination instantaneous/storage water heater system |
| RU2495044C2 (ru) * | 2007-08-29 | 2013-10-10 | Метилджен Инк. | Ингибиторы активности протеинтирозинкиназы |
| EP2262815A4 (en) * | 2008-03-05 | 2012-04-11 | Methylgene Inc | Inhibitors of protein intolerance activity |
| JP2013525286A (ja) * | 2010-04-16 | 2013-06-20 | メチルジーン・インコーポレイテッド | タンパク質チロシンキナーゼ活性の阻害剤 |
-
2009
- 2009-02-27 EP EP09716596A patent/EP2262815A4/en not_active Withdrawn
- 2009-02-27 CA CA2717816A patent/CA2717816A1/en not_active Abandoned
- 2009-02-27 SG SG2012040093A patent/SG182146A1/en unknown
- 2009-02-27 NZ NZ588355A patent/NZ588355A/en not_active IP Right Cessation
- 2009-02-27 BR BRPI0908573-4A patent/BRPI0908573A2/pt not_active IP Right Cessation
- 2009-02-27 JP JP2010548992A patent/JP2011513339A/ja active Pending
- 2009-02-27 AR ARP090100693A patent/AR070539A1/es unknown
- 2009-02-27 US US12/920,676 patent/US8729268B2/en not_active Expired - Fee Related
- 2009-02-27 RU RU2010140668/04A patent/RU2533827C2/ru not_active IP Right Cessation
- 2009-02-27 UA UAA201011785A patent/UA101362C2/ru unknown
- 2009-02-27 WO PCT/CA2009/000228 patent/WO2009109035A1/en active Application Filing
- 2009-02-27 KR KR1020107025059A patent/KR20100132068A/ko not_active Application Discontinuation
- 2009-02-27 CN CN200980107358.1A patent/CN102015723B/zh not_active Expired - Fee Related
- 2009-02-27 AU AU2009221583A patent/AU2009221583B2/en not_active Ceased
- 2009-02-27 BR BRPI0923670-8A patent/BRPI0923670A2/pt not_active IP Right Cessation
- 2009-02-27 RU RU2010145459/04A patent/RU2498988C2/ru not_active IP Right Cessation
- 2009-02-27 NZ NZ589336A patent/NZ589336A/en not_active IP Right Cessation
- 2009-02-27 KR KR1020107022142A patent/KR20100137495A/ko not_active Application Discontinuation
- 2009-02-27 MX MX2010009729A patent/MX2010009729A/es not_active Application Discontinuation
- 2009-02-27 CN CN201010549696.5A patent/CN102161663B/zh not_active Expired - Fee Related
- 2009-02-27 UA UAA201013462A patent/UA100262C2/uk unknown
- 2009-02-27 CA CA2763168A patent/CA2763168A1/en not_active Abandoned
- 2009-02-27 TW TW098106618A patent/TW200940549A/zh unknown
- 2009-02-27 TW TW099142241A patent/TWI438205B/zh not_active IP Right Cessation
- 2009-02-27 EP EP10015089A patent/EP2332536A1/en not_active Withdrawn
-
2010
- 2010-08-17 ZA ZA2010/05868A patent/ZA201005868B/en unknown
- 2010-09-02 IL IL207946A patent/IL207946A0/en unknown
- 2010-10-01 CO CO10121775A patent/CO6290684A2/es active IP Right Grant
- 2010-10-21 ZA ZA2010/07517A patent/ZA201007517B/en unknown
- 2010-10-21 IL IL208882A patent/IL208882A0/en unknown
- 2010-11-26 AR ARP100104383A patent/AR079208A2/es unknown
- 2010-11-30 AU AU2010246540A patent/AU2010246540B2/en not_active Ceased
- 2010-12-09 US US12/964,289 patent/US8759522B2/en not_active Expired - Fee Related
-
2011
- 2011-01-21 JP JP2011010326A patent/JP5661485B2/ja not_active Expired - Fee Related
-
2014
- 2014-02-28 US US14/194,155 patent/US20140179632A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070539A1 (es) | Inhibidores de la actividad de proteina tirosina quinasa | |
| PE20220597A1 (es) | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos | |
| AR080878A1 (es) | Derivados heterociclicos de ariletinilo, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de la esquizofrenia y trastornos cognitivos. | |
| TW200744587A (en) | Azaindole derivatives exhibiting PGD2 receptor antagonism | |
| AR077975A1 (es) | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina | |
| RS53108B (en) | AMINO-1,3,5-TRIAZINES N-REPLACED BY CHIRAL BICYCLIC RADICALS, THE PROCESS FOR THEIR PREPARATION, THEIR COMPOUNDS AND THEIR APPLICATIONS AS HERBICIDES AND PLANT GROWTH REGULATORS | |
| TW200718692A (en) | Dihydrobenzofuran derivatives and uses thereof | |
| TW200800938A (en) | Indole carboxylic acid derivatives exhibiting PGD2 receptor antagonism | |
| ECSP045317A (es) | Piridinoilpiperidinas como agonistas de 5-ht1f | |
| PE20220905A1 (es) | Pirroles triciclicos condensados como moduladores de alfa-1 antitripsina | |
| CO6170361A2 (es) | Composiciones y metodos para modular receptores de c-kit y pdgfr | |
| TW200643015A (en) | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives | |
| AR052887A1 (es) | Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa | |
| MY197875A (en) | Cap-dependent endonuclease inhibitors | |
| AR049276A1 (es) | Compuestos carboxamidos opiodes y composiciones farmaceuticas que los contienen | |
| TW200734322A (en) | Indole derivatives exhibiting PGD2 receptor antagonism | |
| BRPI0410720A (pt) | quinazolinas e pirido[3,4-d]pirimidinas como inibidores do receptor de tirosina cinase | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR075597A1 (es) | Derivados de indol como antagonistas de receptores crth2, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del asma y otras enfermedades alergicas . | |
| MX2019012336A (es) | Compuestos inhibidores del transportador vesicular de monoaminas 2 (vmat2) y composiciones de los mismos. | |
| AR059328A1 (es) | Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| NO20091590L (no) | Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer | |
| AR079467A1 (es) | Derivados heterociclicos nitrogenados de etinilo, composiciones farmaceuticas que los contienen, proceso para prepararlos y uso de los mismos para tratar y/o prevenir enfermedades cognitivas o esquizofrenia. | |
| EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |